Best practice portal main page
Buprenorphine vs methadone substitution to retain patients in treatment
Summary of the evidence
Methadone maintenance therapy was found to be statistically more effective than Buprenorphine maintenance therapy in a systematic review (Mattick et al., 2014) in:
- improving retention in treatment
- in flexible doses studies (RR 0.83, 95 % CI 0.72 to 0.95, 5 studies, N=788);
- in low doses studies (MMT ≤ 40mg BUP 2-6mg) (RR 0.67, 95 % CI 0.52 to 0.87, 3 studies, N=253);
- no difference was observed in reduction of opioid use as measured by urinalysis (SMD -0.11; 95 % CI -0.23 to 0.02, 8 studies, N=1027) or self-reported (SMD -0.11; 95 % CI -0.28 to 0.07, 4 studies, N=501)
However, at medium doses (MMT 40-85mg, BUP 7-15mg) and high doses (MMT ≥ 16mg, BUP ≥ 85mg) no difference was found between Methadone and Buprenorphine treatment in:
- improving retention in treatment
- medium doses (RR 0.87, 95 % CI 0.69 to 1.10, 7 studies, N=780)
- high doses (RR 0.79, 95 % CI 0. 02 to 3.16, 1 study, N=134)
- reducing opioid use as measured by urinalysis or self-reported
A new systematic review with network meta-analysis (Lim et al., 2022, 79 RCTs) confirmed the results and found a significant overall effect of Methadone in:
- retaining people in treatment (RR 2.62, 95 % CI 2.09 to 3.33) compared to control
- in the network analysis Methadone was the highest ranked intervention (Surface Under the Cumulative Ranking [SUCRA] = 0.901) with control being the lowest (SUCRA = 0.000). Methadone was superior to buprenorphine for treatment retention (RR = 1.22; 95% CI = 1.06-1.40) yet buprenorphine superior to naltrexone (RR = 1.39; 95% CI = 1.10-1.80).
In a more recent systematic review with meta-analysis (Degenhardt et al., 2023, 32 RCTs), the primary outcomes considered were retention in treatment, treatment adherence, and extra-medical opioid use; the following results were concluded:
- For retention beyond one month, methadone had higher retention rates compared to buprenorphine (RR 0.76, 95% CI 0.67–0.85; I²=74.2%; 16 studies, N=3151)
- For extra-medical opioid use, there is some evidence indicating lower rates of buprenorphine compared to methadone as measured by urinalysis (–0.20, 95% CI –0.29 to –0.11; I²=0.0%; 3 studies, N=841)
To summarise, the authors highlight that while methadone may have better treatment retention rates, there are few differences in other comparative outcomes. Therefore, it is important to consider other factors and take a client-centered approach when prescribing.
Details
Note: this evidence summary is only valid for the outcomes, target groups, settings and substances/patterns of use described below.